Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Crescent Biopharma (CBIO) Interest & Investment Income (2020 - 2025)

Crescent Biopharma (CBIO) has disclosed Interest & Investment Income for 8 consecutive years, with $2.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Interest & Investment Income changed N/A to $2.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.6 million, a N/A change, with the full-year FY2025 number at $2.9 million, up 207.4% from a year prior.
  • Interest & Investment Income was $2.0 million for Q4 2025 at Crescent Biopharma, up from $55140.0 in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $2.0 million in Q4 2025 to a low of $4076.0 in Q4 2021.
  • A 5-year average of $355311.8 and a median of $243598.0 in 2022 define the central range for Interest & Investment Income.
  • Peak YoY movement for Interest & Investment Income: crashed 98.69% in 2021, then soared 9180.3% in 2022.
  • Crescent Biopharma's Interest & Investment Income stood at $4076.0 in 2021, then skyrocketed by 9180.3% to $378265.0 in 2022, then soared by 35.41% to $512194.0 in 2023, then plummeted by 63.97% to $184520.0 in 2024, then surged by 1010.9% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for CBIO's Interest & Investment Income are $2.0 million (Q4 2025), $55140.0 (Q1 2025), and $184520.0 (Q3 2024).